These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 29672472)

  • 41. Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age.
    Avdicova M; Crasta PD; Hardt K; Kovac M
    Vaccine; 2015 May; 33(23):2727-33. PubMed ID: 24962750
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Advisory committee on immunization practices recommended immunization schedules for persons aged 0 through 18 years--United States, 2015.
    Strikas RA; ; ;
    MMWR Morb Mortal Wkly Rep; 2015 Feb; 64(4):93-4. PubMed ID: 25654610
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients.
    Tong NK; Beran J; Kee SA; Miguel JL; Sánchez C; Bayas JM; Vilella A; de Juanes JR; Arrazola P; Calbo-Torrecillas F; de Novales EL; Hamtiaux V; Lievens M; Stoffel M
    Kidney Int; 2005 Nov; 68(5):2298-303. PubMed ID: 16221232
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014.
    Centers for Disease Control and Prevention (CDC)
    MMWR Recomm Rep; 2013 Sep; 62(RR-07):1-43. PubMed ID: 24048214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Chesson HW; Curtis CR; Gee J; Bocchini JA; Unger ER;
    MMWR Recomm Rep; 2014 Aug; 63(RR-05):1-30. PubMed ID: 25167164
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Testing of CpG-optimized protein and DNA vaccines against the hepatitis B virus in chimpanzees for immunogenicity and protection from challenge.
    Payette PJ; Ma X; Weeratna RD; McCluskie MJ; Shapiro M; Engle RE; Davis HL; Purcell RH
    Intervirology; 2006; 49(3):144-51. PubMed ID: 16428890
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatitis B vaccination coverage among high-risk adults 18-49 years, U.S., 2009.
    Lu PJ; Byrd KK; Murphy TV; Weinbaum C
    Vaccine; 2011 Sep; 29(40):7049-57. PubMed ID: 21782873
    [TBL] [Abstract][Full Text] [Related]  

  • 48. School-based adolescent hepatitis B vaccination.
    Cassidy WM
    J La State Med Soc; 1999 Dec; 151(12):622-6. PubMed ID: 10643204
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus.
    Marks KM; Kang M; Umbleja T; Avihingsanon A; Sugandhavesa P; Cox AL; Vigil K; Perazzo H; Price JC; Katsidzira L; Vernon C; Alston-Smith B; Sherman KE;
    Clin Infect Dis; 2023 Aug; 77(3):414-418. PubMed ID: 37017075
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine - Advisory Committee on Immunization Practices, 2016.
    Patton ME; Stephens D; Moore K; MacNeil JR
    MMWR Morb Mortal Wkly Rep; 2017 May; 66(19):509-513. PubMed ID: 28520709
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine.
    Shafran SD; Mashinter LD; Lindemulder A; Taylor GD; Chiu I
    HIV Med; 2007 Jul; 8(5):295-9. PubMed ID: 17561875
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule.
    Connor BA; Blatter MM; Beran J; Zou B; Trofa AF
    J Travel Med; 2007; 14(1):9-15. PubMed ID: 17241248
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age.
    Halperin SA; Ward B; Cooper C; Predy G; Diaz-Mitoma F; Dionne M; Embree J; McGeer A; Zickler P; Moltz KH; Martz R; Meyer I; McNeil S; Langley JM; Martins E; Heyward WL; Martin JT
    Vaccine; 2012 Mar; 30(15):2556-63. PubMed ID: 22326642
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials.
    Alavian SM; Tabatabaei SV
    Clin Ther; 2010 Jan; 32(1):1-10. PubMed ID: 20171406
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunization recommendations expanded for hepatitis B, HPV, pertussis vaccines.
    Kuehn BM
    JAMA; 2012 Apr; 307(13):1353-4. PubMed ID: 22474190
    [No Abstract]   [Full Text] [Related]  

  • 56. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC).
    Wharton M; Strikas RA; Harpaz R; Rotz LD; Schwartz B; Casey CG; Pearson ML; Anderson LJ; ;
    MMWR Recomm Rep; 2003 Apr; 52(RR-7):1-16. PubMed ID: 12710832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Update From the Advisory Committee on Immunization Practices.
    O'Leary ST; Maldonado YA; Byington CL
    J Pediatric Infect Dis Soc; 2017 Sep; 6(3):215-218. PubMed ID: 28903515
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Baseline hepatitis B vaccination coverage among persons with diabetes before implementing a U.S. recommendation for vaccination.
    Byrd KK; Lu PJ; Murphy TV
    Vaccine; 2012 May; 30(23):3376-82. PubMed ID: 22472793
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials.
    Fabrizi F; Dixit V; Messa P; Martin P
    Vaccine; 2012 Mar; 30(13):2295-300. PubMed ID: 22285268
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessing the cost-utility of preferentially administering Heplisav-B vaccine to certain populations.
    Rosenthal EM; Hall EW; Rosenberg ES; Harris A; Nelson NP; Schillie S
    Vaccine; 2020 Dec; 38(51):8206-8215. PubMed ID: 33160756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.